Tomohisa Nezu1,2, Takaya Kitano3, Satoshi Kubo3, Junichi Uemura3, Shinji Yamashita3, Takeshi Iwanaga3,4, Takeshi Inoue3, Naohisa Hosomi5, Hirofumi Maruyama5, Masayasu Matsumoto5,6, Kazumi Kimura7, Yoshiki Yagita3. 1. Department of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan. tomonezu@hiroshima-u.ac.jp. 2. Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. tomonezu@hiroshima-u.ac.jp. 3. Department of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan. 4. Department of Stroke Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan. 5. Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. 6. Hoshigaoka Medical Center, Japan Community Healthcare Organization (JCHO), Hirakata, Japan. 7. Department of Neurological Science, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Abstract
BACKGROUND: D-dimer levels are used in several clinical settings, such as in predicting venous thrombosis, cardioembolic stroke and cancer status. In the present study, we investigated the associations between plasma D-dimer levels at admission, clinical characteristics and mortality at discharge in cryptogenic stroke patients. We also investigated whether D-dimer levels can predict long-term outcomes in those patients, including those with and without right-to-left shunt (RLS). METHODS: Acute cryptogenic stroke patients (n = 295, 72 ± 13 years old) were consecutively enrolled and retrospectively analyzed. We defined the cryptogenic stroke as an undetermined etiology according to the Trial of Org 10172 in Acute Stroke Treatment criteria. Plasma D-dimer levels at admission were evaluated. Assessments for RLS were performed using saline contrast-transcranial Doppler ultrasonography or contrast-transesophageal echography. Survivors (at discharge) underwent follow-up for up to 3 years after stroke onset. RESULTS: Of the total enrolled cohort, 17 patients died at discharge. D-dimer levels correlated with initial National Institutes of Health Stroke Scale (NIHSS) score (r = 0.391, P < 0.001) and were associated with mortality at discharge [odds ratio 1.04; 95% confidence interval (CI) 1.00-1.08, P = 0.049] after adjusting for age, sex and initial NIHSS score. Of the 278 survivors at discharge, 266 patients were evaluated to assess RLS during hospitalization, and 62 patients (23.3%) exhibited RLS. According to the median plasma D-dimer levels at admission (0.7 µg/ml), the patients were divided into a low D-dimer group (n = 136, < median) and a high D-dimer group (n = 130, ≥ median). Patients in the high D-dimer group were older, more frequently female, had a lower BMI, had a higher prevalence of cancer and had greater initial neurological severity compared to the patients in the low D-dimer group. During the follow-up period (median, 1093 days), 31 patients developed recurrent stroke and 33 patients died. High D-dimer levels at admission were independently associated with recurrent stroke and all-cause mortality [hazard ratio (HR) 3.76; 95% CI 1.21-14.1, P = 0.021) in patients with RLS, but not in those without RLS (HR 1.35; 95% CI 0.74-2.50, P = 0.335). CONCLUSIONS: Increased D-dimer levels at admission were associated with mortality at discharge in cryptogenic stroke patients. In addition, high D-dimer levels were also associated with long-term outcomes in cryptogenic stroke patients with RLS.
BACKGROUND: D-dimer levels are used in several clinical settings, such as in predicting venous thrombosis, cardioembolic stroke and cancer status. In the present study, we investigated the associations between plasma D-dimer levels at admission, clinical characteristics and mortality at discharge in cryptogenic strokepatients. We also investigated whether D-dimer levels can predict long-term outcomes in those patients, including those with and without right-to-left shunt (RLS). METHODS: Acute cryptogenic strokepatients (n = 295, 72 ± 13 years old) were consecutively enrolled and retrospectively analyzed. We defined the cryptogenic stroke as an undetermined etiology according to the Trial of Org 10172 in Acute Stroke Treatment criteria. Plasma D-dimer levels at admission were evaluated. Assessments for RLS were performed using saline contrast-transcranial Doppler ultrasonography or contrast-transesophageal echography. Survivors (at discharge) underwent follow-up for up to 3 years after stroke onset. RESULTS: Of the total enrolled cohort, 17 patients died at discharge. D-dimer levels correlated with initial National Institutes of Health Stroke Scale (NIHSS) score (r = 0.391, P < 0.001) and were associated with mortality at discharge [odds ratio 1.04; 95% confidence interval (CI) 1.00-1.08, P = 0.049] after adjusting for age, sex and initial NIHSS score. Of the 278 survivors at discharge, 266 patients were evaluated to assess RLS during hospitalization, and 62 patients (23.3%) exhibited RLS. According to the median plasma D-dimer levels at admission (0.7 µg/ml), the patients were divided into a low D-dimer group (n = 136, < median) and a high D-dimer group (n = 130, ≥ median). Patients in the high D-dimer group were older, more frequently female, had a lower BMI, had a higher prevalence of cancer and had greater initial neurological severity compared to the patients in the low D-dimer group. During the follow-up period (median, 1093 days), 31 patients developed recurrent stroke and 33 patients died. High D-dimer levels at admission were independently associated with recurrent stroke and all-cause mortality [hazard ratio (HR) 3.76; 95% CI 1.21-14.1, P = 0.021) in patients with RLS, but not in those without RLS (HR 1.35; 95% CI 0.74-2.50, P = 0.335). CONCLUSIONS: Increased D-dimer levels at admission were associated with mortality at discharge in cryptogenic strokepatients. In addition, high D-dimer levels were also associated with long-term outcomes in cryptogenic strokepatients with RLS.
Authors: Ji Won Kim; Suk Jae Kim; Cindy W Yoon; Chang-Hyun Park; Kun Woo Kang; Soo Kyoung Kim; Yun-Hee Kim; Oh Young Bang Journal: Int J Stroke Date: 2012-07-19 Impact factor: 5.266
Authors: Michael Marnane; Caroline A Duggan; Orla C Sheehan; Aine Merwick; Niamh Hannon; Denis Curtin; Dawn Harris; Emma B Williams; Gillian Horgan; Lorraine Kyne; Patricia M E McCormack; Joseph Duggan; Alan Moore; Gloria Crispino-O'Connell; Peter J Kelly Journal: Stroke Date: 2010-07-01 Impact factor: 7.914
Authors: David J Gladstone; Melanie Spring; Paul Dorian; Val Panzov; Kevin E Thorpe; Judith Hall; Haris Vaid; Martin O'Donnell; Andreas Laupacis; Robert Côté; Mukul Sharma; John A Blakely; Ashfaq Shuaib; Vladimir Hachinski; Shelagh B Coutts; Demetrios J Sahlas; Phil Teal; Samuel Yip; J David Spence; Brian Buck; Steve Verreault; Leanne K Casaubon; Andrew Penn; Daniel Selchen; Albert Jin; David Howse; Manu Mehdiratta; Karl Boyle; Richard Aviv; Moira K Kapral; Muhammad Mamdani Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245
Authors: Liu Tong; Jun Zheng; You-Cong Zhang; Kai Zhu; Hui-Qiang Gao; Kai Zhang; Xiu-Feng Jin; Shang-Dong Xu Journal: Front Physiol Date: 2020-01-21 Impact factor: 4.566
Authors: Minho Han; Young Dae Kim; Hyung Jong Park; In Gun Hwang; Junghye Choi; Jimin Ha; Ji Hoe Heo; Hyo Suk Nam Journal: PLoS One Date: 2019-01-02 Impact factor: 3.240